Vertex Pharmaceuticals Incorporated faces slowing Trikafta/Kaftrio sales and a stock-price divergence with peers. Click for ...
Vertex, Inc. is rated a Buy due to steady growth, margin expansion, recurring revenue, and high retention. Learn more about ...
Some things will remain the same for Vertex five years from now, including its dominance in treating cystic fibrosis (CF). However, the company will likely achieve success in several new markets ...
During a virtual keynote at Google I/O 2021, Google’s developer conference, Google announced the launch in general availability of Vertex AI, a managed AI platform. It’s designed to help companies to ...